SCOR: Pathobiology of Fibrotic Lung Disease
SCOR: Pathobiology of Fibrotic Lung Disease
批准号:
6346865
负责人:
ROBERT James MASON
金额:
$169.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-05 至 2006-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(Applicant's Abstract) The overall purpose of this SCOR proposal is to
investigate the role of the myofibroblast in idiopathic pulmonary fibrosis
(IPF). We are particularly interested in defining the source and regulation of
TGF-beta production, especially the contribution of the ingestion of apoptotic
cells and cell debris, the relationship of paracrine factors and mechanical
factors on myofibroblast gene regulation, the role of survival factors for
myofibroblasts such as IGF- I and myofibroblast apoptosis, interactions of
myofibroblasts with alveolar epithelial cells, and finally regulation by
interferon gamma (INF). In the clinical portion of this SCOR proposal, Dr.
Schwarz will evaluate INF in the treatment of idiopathic pulmonary fibrosis. A
major aspect of this proposal will be to use DNA microarrays to define gene
expression of specific cell types as well as alterations in fibrotic lung and
microdissected fibroblastic foci in IPF and Masson bodies in BOOP. In
project 1, Dr. Henson will study the regulation of TGF-beta production by the
ingestion of apoptotic cells. This is a new biologic process for the
production of TGF-beta. In project 2, Dr. Worthen will study the regulation
of the myofibroblast phenotype especially the interaction between paracrine
factors such as TGF-beta and mechanical stress. In project 3, Dr. Riches will
determine the role of IGF-1 as a survival factor which prevents the apoptosis
of myofibroblasts. In project 4, Dr. Mason will study the interactions between
myofibroblasts and alveolar type II cells. A significant portion of this
project is to define the interactions between KGF, TGF-beta, and INF on the
alveolar epithelium. In project 5, Dr. Schwarz will determine the clinical
efficacy of INF as therapy for idiopathic pulmonary fibrosis, myofibroblast
proliferation and apoptosis in IPF, and gene expression in fibroblastic foci
in IPF and Masson bodies of BOOP.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1136/thorax.55.6.502
发表时间:
2000
期刊:
Thorax
影响因子:
10
作者:
[Schwarz,MI, Brown,KK]
通讯作者:
Brown,KK
Expression of CINC-2beta is related to the state of differentiation of alveolar epithelial cells.
CINC-2β的表达与肺泡上皮细胞的分化状态有关。
DOI:
10.1165/rcmb.2005-0113oc
发表时间:
2005
期刊:
American journal of respiratory cell and molecular biology
影响因子:
6.4
作者:
[Nishina,Kahoru, Zhang,Feijie, Nielsen,LarryD, Edeen,Karen, Wang,Jieru, Mason,RobertJ]
通讯作者:
Mason,RobertJ
Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis.
血管炎:韦格纳肉芽肿病、Churg-Strauss综合征、显微镜下多血管炎、结节性多动脉炎和大动脉炎。
DOI:
10.1016/s0749-0704(02)00031-3
发表时间:
2002
期刊:
Critical care clinics
影响因子:
4.3
作者:
[Frankel,StephenK, Sullivan,EugeneJ, Brown,KevinK]
通讯作者:
Brown,KevinK
Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor.
转化生长因子-β 拮抗角化细胞生长因子诱导的肺泡 II 型细胞增殖。
DOI:
10.1165/rcmb.2004-0182oc
发表时间:
2004
期刊:
American journal of respiratory cell and molecular biology
影响因子:
6.4
作者:
[Zhang,Feijie, Nielsen,LarryD, Lucas,JosephJ, Mason,RobertJ]
通讯作者:
Mason,RobertJ
DOI:
10.1513/pats.200511-120jh
发表时间:
2006-01-01
期刊:
Proceedings of the American Thoracic Society
影响因子:
--
作者:
[Brown, Kevin K]
通讯作者:
Brown, Kevin K
共 7 条
Air/liquid interface cultures for alveolar type II cell differentiation
-
批准号:8191639
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2011
-
负责人:ROBERT James MASON
-
依托单位:
Air/liquid interface cultures for alveolar type II cell differentiation
-
批准号:8279217
-
项目类别:
-
资助金额:$19.81万
-
财政年份:2011
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8074270
-
项目类别:
-
资助金额:$24.72万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8260411
-
项目类别:
-
资助金额:$43.38万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8063939
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:7679879
-
项目类别:
-
资助金额:$42.99万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:7787530
-
项目类别:
-
资助金额:$43.84万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8456892
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7720949
-
项目类别:
-
资助金额:$26.53万
-
财政年份:2008
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7610721
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2007
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7382170
-
项目类别:
-
资助金额:$26.61万
-
财政年份:2006
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7171395
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2005
-
负责人:ROBERT James MASON
-
依托单位:
CORE--DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:6973095
-
项目类别:
-
资助金额:$51.19万
-
财政年份:2004
-
负责人:ROBERT James MASON
-
依托单位:
Type II Pneumocyte Interactions with SARS-CoV
-
批准号:6797025
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2003
-
负责人:ROBERT James MASON
-
依托单位:
Conference:Lung Surfactant:Cellular & Molecular Biology
-
批准号:6507112
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2002
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar epithelium in pulmonary fibrosis
-
批准号:6616356
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2002
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6785314
-
项目类别:
-
资助金额:$183.09万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6912712
-
项目类别:
-
资助金额:$188.58万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6573340
-
项目类别:
-
资助金额:$173.22万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6616116
-
项目类别:
-
资助金额:$177.76万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
海外基金